One More Big Pharma Bribery Scandal?

Big pharma company Eli Lilly (NYSE: LLY  ) faces allegations of bribing medical doctors in China, just weeks after similar claims arose against its peers GlaxoSmithKline and Sanofi. In the following video, taken from The Motley Fool's health-care show, analysts David Williamson and Max Macaluso discuss this story and the potential impact of these claims on investors.

Take a moment to look past these recent scandals, and you'll see that one of the best parts of owning big pharma stocks is their attractive dividends. But smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

Read/Post Comments (0) | Recommend This Article (1)

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2612768, ~/Articles/ArticleHandler.aspx, 8/23/2016 5:32:04 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,547.30 17.88 0.10%
S&P 500 2,186.90 4.26 0.20%
NASD 5,260.08 15.48 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/23/2016 4:00 PM
LLY $79.57 Up +0.28 +0.35%
Eli Lilly and Co. CAPS Rating: ***